New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

41

Explainer: What does FDA approval of Biogen’s Alzheimer’s drug mean for patients?

The U.S. Food and Drug Administration approved Biogen’s aducanumab, the first drug to target an underlying cause of Alzheimer’s disease. The drug, to be sold under the brand Aduhelm, is the first new approval of an Alzheimer’s drug since 2003 and the only treatment designed to slow progression of the mind-robbing disease.

43

Ashfield Health expands allegro. model and launches innovative allegro.EXCEL program

Following huge success over the past 3.5 years, the allegro. accelerated learning and development model is adding a new program to its portfolio. The launch of allegro.EXCEL provides structured career development for senior medical writers to accelerate their career to scientific leadership positions in Ashfield Health.

45

U.S. approval of Biogen Alzheimer’s drug sends shares soaring, hailed as ‘big day” for patients

U.S. regulators on June 7 approved Biogen Inc.’s aducanumab as the first treatment to attack a likely cause of Alzheimer’s disease despite controversy over whether the clinical evidence proves the drug works, sending the company’s shares soaring.

49

Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgAN

Novartis announced Phase II primary endpoint data showing the investigational, first-in-class, oral, targeted factor B inhibitor iptacopan reduced protein in the urine – an increasingly recognized surrogate marker correlating with progression to kidney failure – and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN).

50

HIV Epidemic: 40 Years Later

On June 5, the United States and the rest of the world marks a grim milestone – the 40th anniversary of the HIV epidemic. While the virus has taken the lives of an estimated 35 million people over the last 40 years, an end could be in sight as biopharma researchers continue to develop safe and effective new treatments, with an eye toward a potential cure.